Beyond Biotech - the podcast from Labiotech

Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated within the tumor, making it a highly-targeted solution.This differentiated approach overcomes the limits of existing treatments, such as small molecule or antibody-drug conjugates. It could also be more cost effective than many advanced, far cell and gene therapy alternatives. Seekyo is looking for clinical entry to target four of the more challenging solid cancers - pancreas, TNBC, colorectal and lung, in an umbrella PhI/IIa. This will demonstrate safety and initial efficacy readings whilst at the same time defining the lead indication to progress to later-stage development. This week, our guest is Seekyo Therapeutics’ CEO, Oury Chetboun. 00:38-01:57: About Seekyo Therapeutics01:57-03:17: The challenges of treating solid tumors03:17-06:08: What is Tumor Activated Therapy?06:08-07:46: What is SKY01?07:46-08:10: What happens to the cancer cells?08:10-09:52: Does the tumor vanish? 09:52-10:16: How is it delivered?10:16-11:30: Are other companies working on tumor-activated therapies?11:30-13:09: What treatment options are being worked on for solid tumors?13:09-13:47: Long-lasting treatment13:47-15:33: Clinical trials15:33-16:22: Timelines16:22-18:08: Does the treatment have other potential applications?18:08-19:59: Cost effectiveness19:59-21:59: Is the goal to cure people? 21:59-22:46: Treatment frequency22:46-24:00: The impact of tumor size24:00-25:23: Seekyo Therapeutics’ pipeline 25:23-27:27: Fund-raising27:27-30:33: Reaction to the therapyInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.While there weren’t necessarily many financial blockbusters, there were plenty of announcements and discussions on everything from artificial intelligence to the rising influence of Chinese companies and research, to the potential ramifications of the incoming Trump administration in the U.S.To help us navigate some of the highlights of the event, we spoke with Orca Bio’s co-founder and CEO, Ivan Dimov, and also Parabilis Medicines’ chief business officer, Greg Miller.02:01-03:53: About Orca Bio 03:53-05:43: JPM highlights05:43-07:26: Stand-out deals and announcements07:26-09:01: Were any sectors more prominent than others?09:01-12:38: About Parabilis Medicines12:38-13:58: JPM highlights13:58-16:33: Stand-out deals and announcements  16:33-17:53: Were any sectors more prominent than others?17:53-19:17: Was there an optimistic mood?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund.Initiate Ventures is shaking up the traditional venture capital model by blending investments in healthcare, life sciences, and technology with a company creation platform. The company is tackling some of the most pressing challenges in healthcare, and their innovative approach offers fresh insights into what it takes to scale transformative startups.Owens was the co-founder of GRAIL (acquired by Illumina for $8bn) and was a partner at Kleiner Perkins, where she helped shape some of the most successful health tech startups. Dimkova is a former healthcare technology investor at GE Ventures, who also scaled a company that raised more than $700m and built one of the largest radiation therapy networks in the US.Their approach is reflected in their dual model: funding existing companies while also co-creating ventures alongside founders in their startup studio. They helped launch groundbreaking companies like Macro Trials, a precision clinical research platform, and Persana, a leader in oncology diagnostics.This week on the podcast, we have a conversation with one of the co-founders of the company, Jessica Owens.00:40-05:19: About Initiate Ventures05:19-08:33: What sets Initiate Ventures apart from other venture funds?08:33-10:59: Revitalizing healthcare10:59-13:46: Determining realistic company visions13:46-15:15: Initiate Ventures and Initiate Studios15:15-19:50: Working with companies19:50-21:36: Working with new companies21:36-23:00: Evaluating potential success23:00-24:40: How hands on is Initiate Ventures?24:40-28:24: Is there a change in what attracts capital?28:24-30:02: Infectious disease – a neglected area30:02-33:08: How important are ESG considerations?33:08-35:42: Trends for 202535:42-36:42: Goals for 2025Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, injectable pain relief solutions.As part of the NIH's efforts to tackle the U.S. opioid crisis, the funding will advance research into safer, drug-free alternatives to opioid pain management. Brixton’s Neural Ice is an injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain.On the podcast this week, we have a conversation with Sameer Sabir, CEO and co-founder of Brixton Biosciences, to dive deeper into pain treatment, the opioid crisis, and Brixton’s mission.01:05-02:47: About Brixton Biosciences02:47-03:39: Brixton’s pipeline 03:39-07:46: The opioid crisis07:46-08:41: The extent of the crisis08:41-12:00: Current alternatives to opioids12:00-12:40: Managing pain12:40-17:19: How was Neural ice developed?17:19-18:33: Duration of treatment18:33-21:01: Suitability for different levels of pain21:01-21:31: Speed of effect21:31-22:37: Side effects22:37-24:18: Opioids vs. non-opioids24:18-25:33: Are there different responses to Neural Ice?25:33-26:29: Standardized doses26:29-27:42: Pricing 27:42-28:49: Other work on alternatives to opioids28:49-30:45: Challenges to developing new pain treatments30:45-31:57: Other priorities at Brixton31:57-32:16: Timeline for Neural Ice Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!On this podcast, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D.The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company’s cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles.Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund.Softbank Vision Fund is the world’s largest technology-focused investment fund, with $166bn assets under management, and a portfolio of more than 250 companies.In the discussion, we cover investment trends within life sciences, the European health and biotech scene, as well as the precise applications of new and emerging AI technologies. We also look ahead to what the biotech and life sciences fields may hold in 2025.00:55-02:03: About the SoftBank Vision Fund02:03-02:47: Developing timelines02:47-04:27: Managing a large portfolio04:27-11:18: Portfolio company profiles11:18-13:36: Investment criteria13:36-17:06: Trends in funding17:06-19:09: Effects of the US election19:09-21:45: How can companies reduce risk and raise funds?21:45-25:25: What sectors are attracting interest currently?25:25-27:49: Focusing on patients not profits27:49-29:53: The impact of AI 29:53-31:45: Focus on applications31:45-35:24: Trends in European biotech funding35:24-38:19: Trends for 2025Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens.IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001 combats peanut allergies by blocking the allergic cascade and reducing risk of anaphylaxis.Should IGNX001 prove successful, it will provide a promising solution for peanut allergies and pave the way for IgGenix's technology to be applied to other types of food allergies and allergic diseases.Our guest on the podcast this week is Jessica Grossman, chief executive officer of IgGenix.01:14-02:51: About IgGenix02:51-06:30: About peanut allergy06:30-07:31: Are allergies on the rise?07:31-08:46: Are allergy responses similar?08:46-10:13: The problems with treating allergies10:13-13:53: Current treatments for peanut allergy13:53-15:45: The challenges of developing drugs to treat allergies15:45-16:54: Overcoming the placebo effect16:54-18:18: Are other companies working on allergy treatments?18:18-21:32: IgGenix’s SEQ SIFTER platform21:32-24:20: About IgGenix’s IGNX00124:20-24:42: Repeat doses24:42-26:19: Could peanut allergy sufferers eat peanuts?26:19-27:46: Can the technology be adapted to treat other allergies?27:46-28:56: Are there variations in the treatment of different allergies?28:56-29:35: Treatments for other diseases29:35-30:23: The future for people with allergiesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Adam Marťák, founder and CEO of ambiom—a life science advisory firm in Bratislava—shares insights into Eastern Europe's biotech scene. He discusses the challenges startups face, from navigating complex regulations to securing funding. Marťák explains different biotech valuation methods, emphasizing that early-stage companies offer greater upside potential for investors. The conversation also explores how pipeline composition affects success rates and touches on the increasing influence of AI in drug discovery, transforming the investment landscape.

Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever.Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes and, in turn, reduce biting and the threat of disease transmission. Wolbachia-carrying mosquitoes are designed to spread Wolbachia bacteria into the local mosquito population to limit the ability of the remaining infected mosquito population to transmit dengue. The platforms are designed for specific settings and intervention types, and provide options for governments and communities seeking suppression, replacement or hybrid approaches using both.Our guest on the podcast this week is the CEO of Oxitec, Grey Frandsen.00:56-02:12: About Oxitec02:12-05:54: The state of mosquito-borne diseases05:54-07:09: The effect of climate change07:09-08:29: Moving into more developed countries08:29-10:27: Wolbachia replacement technology10:27-12:53: The Sparks program12:53-13:46: Other companies’ approaches13:46-15:00: World Mosquito Program15:00-15:30: Establishing timelines15:30-17:20: The effect on the environment17:20-18:54: Could adaptation render the technology useless?18:54-20:52: Are the Sparks and Friendly programs being used together?20:52-21:57: Do the technologies work differently on different species?21:57-26:28: How to determine rollout conditions26:28-27:19: Are repeat interventions needed?27:19-30:32: Are there limitations based on cost or politics?30:32-33:11: Are the technologies applicable to other problems?33:11-35:08: Is there anything else in Oxitec’s pipeline?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales.However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle.To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen recognition, i.e. the initial detection of a cell by a T-cell. The second is the co-stimulation of non-antigen presenting molecules, which enhances the immune response​. The final step is cytokine-mediated differentiation and expansion, which guides how T-cells target threats. ​Companies have focused on the second two signals, with signal 2 most commonly seen in therapies such as checkpoint inhibitors and monoclonal antibodies. Signal 3, on the other hand, can be primarily seen in therapies for autoimmune disorders, such as anti-TNF and JAK inhibitors.Greywolf Therapeutics is the first company to explore changing signal 1. The company says focusing on signal 1 applies in three key therapeutic areas: oncology, autoimmunity and virology. Greywolf’s first candidate has delivered strong results during its ongoing phase I/II trial in oncology, therefore demonstrating proof-of-mechanism and target engagement, with its next candidate well-progressed in preclinical development in autoimmunity.To tell us more about the company and its work is Pete Joyce, CEO and co-founder of Greywolf Therapeutics.01:19-04:12: About Greywolf Therapeutics04:12-04:51: The origins of the name04:51-06:52: The three ‘signals’ of the mechanics of immunological responses06:52-08:31: Treatments associated with each signal08:31-10:09: Why is step 1 important, and why has it not been investigated for treatments?10:09-11:28: What areas of disease is this applicable to?11:28-12:19: How do you inhibit ERAP?12:19-14:01: Greywolf Therapeutics’ candidates14:01-15:11: How is this an advance on current treatments?15:11-16:05: What is success for patients?16:05-17:20: How does the stage of disease affect treatment?17:20-18:09: Are other companies looking into antigen modulation? 18:09-19:47: Has this led to investment opportunities?19:47-21:15: Next steps21:15-21:55: Do you anticipate more interest in this space?21:55-23:21: Attending events Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter